• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    5/25/23 9:07:01 AM ET
    $ANNX
    $APGN
    $BEAT
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANNX alert in real time by email

    Gainers

    • HeartBeam (NASDAQ:BEAT) stock rose 20.1% to $2.42 during Thursday's pre-market session. The company's market cap stands at $62.6 million.
    • Prelude Therapeutics (NASDAQ:PRLD) shares increased by 11.43% to $5.75. The market value of their outstanding shares is at $275.7 million.
    • Benitec Biopharma (NASDAQ:BNTC) shares rose 10.36% to $0.23. The market value of their outstanding shares is at $6.4 million.
    • Predictive Oncology (NASDAQ:POAI) shares moved upwards by 10.19% to $3.46. The market value of their outstanding shares is at $13.8 million.
    • Bullfrog AI Hldgs (NASDAQ:BFRG) stock increased by 9.71% to $5.42. The company's market cap stands at $32.9 million. The company's, Q1 earnings came out yesterday.
    • Cardio Diagnostics Hldgs (NASDAQ:CDIO) shares increased by 9.16% to $1.44. The market value of their outstanding shares is at $14.3 million.

    Losers

    • Biocept (NASDAQ:BIOC) stock declined by 42.1% to $2.46 during Thursday's pre-market session. The company's market cap stands at $1.4 million.
    • Annexon (NASDAQ:ANNX) stock declined by 34.24% to $3.4. The company's market cap stands at $180.4 million.
    • Enveric Biosciences (NASDAQ:ENVB) stock declined by 14.97% to $4.09. The company's market cap stands at $8.5 million.
    • Minerva Surgical (NASDAQ:UTRS) shares declined by 11.99% to $0.29. The company's market cap stands at $51.8 million.
    • BiomX (AMEX:PHGE) shares declined by 11.43% to $0.31. The company's market cap stands at $14.2 million.
    • Apexigen (NASDAQ:APGN) stock decreased by 11.11% to $0.52. The company's market cap stands at $12.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ANNX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANNX
    $APGN
    $BEAT
    $BFRG

    CompanyDatePrice TargetRatingAnalyst
    Annexon Inc.
    $ANNX
    12/23/2025$16.00Buy
    Chardan Capital Markets
    Heartbeam Inc.
    $BEAT
    12/11/2025$8.00Speculative Buy → Buy
    The Benchmark Company
    Heartbeam Inc.
    $BEAT
    12/8/2025$2.50Buy
    H.C. Wainwright
    Heartbeam Inc.
    $BEAT
    10/31/2025$4.00Buy
    Roth Capital
    Benitec Biopharma Inc.
    $BNTC
    7/7/2025Buy
    TD Cowen
    Benitec Biopharma Inc.
    $BNTC
    12/16/2024$28.00Buy
    H.C. Wainwright
    Benitec Biopharma Inc.
    $BNTC
    12/13/2024$30.00Outperform
    Robert W. Baird
    Benitec Biopharma Inc.
    $BNTC
    10/16/2024$35.00Outperform
    Oppenheimer
    More analyst ratings

    $ANNX
    $APGN
    $BEAT
    $BFRG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by PRESIDENT AND CEO Love Douglas

    4 - Annexon, Inc. (0001528115) (Issuer)

    2/23/26 7:11:22 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF MEDICAL OFFICER Dananberg Jamie was granted 56,250 shares, increasing direct ownership by 77% to 129,402 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    2/23/26 7:09:58 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & CHIEF BUSINESS OFFICER Overdorf Michael was granted 62,500 shares, increasing direct ownership by 50% to 186,964 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    2/23/26 7:08:42 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $APGN
    $BEAT
    $BFRG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital Markets initiated coverage on Annexon with a new price target

    Chardan Capital Markets initiated coverage of Annexon with a rating of Buy and set a new price target of $16.00

    12/23/25 8:41:58 AM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HeartBeam upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded HeartBeam from Speculative Buy to Buy and set a new price target of $8.00

    12/11/25 8:45:10 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    H.C. Wainwright initiated coverage on HeartBeam with a new price target

    H.C. Wainwright initiated coverage of HeartBeam with a rating of Buy and set a new price target of $2.50

    12/8/25 8:34:44 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $ANNX
    $APGN
    $BEAT
    $BFRG
    SEC Filings

    View All

    Bullfrog AI Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)

    2/20/26 8:28:41 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by BiomX Inc.

    10-K - BiomX Inc. (0001739174) (Filer)

    2/19/26 11:16:52 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cardio Diagnostics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

    2/19/26 8:00:30 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ANNX
    $APGN
    $BEAT
    $BFRG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

    As a result of this action, there are no remaining challenges currently pending against Enveric's patent Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the previously announced Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals (Gilgamesh) against Enveric's issued U.S. Patent No. 12,138,276 (the '276 patent) has been withdrawn. This action follows Enveric's filing of a Request for Discretionary Denial of the petition. As a result of this action, there are no remaining challenges currently pending agai

    2/25/26 8:00:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference

    BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president and chief executive officer, will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 9:50 a.m. ET. A live webcast of the event can be accessed under the ‘Events & Presentations' section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation. About Annexon

    2/24/26 8:00:00 AM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference

    -Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first Cohort 1 Patient, and interim clinical study results for the first Cohort 2 Patient will be reported in a late-breaking poster presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference on March 9, 2026- HAYWARD, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-dir

    2/23/26 7:00:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $APGN
    $BEAT
    $BFRG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Carson William H. bought $20,657 worth of shares (4,115 units at $5.02), increasing direct ownership by 8% to 54,405 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    1/2/26 4:30:06 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Suvretta Capital Management, Llc bought $1,903,133 worth of shares (144,223 units at $13.20) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    12/29/25 7:31:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Suvretta Capital Management, Llc bought $538,972 worth of shares (46,141 units at $11.68) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    12/22/25 7:45:03 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $APGN
    $BEAT
    $BFRG
    Leadership Updates

    Live Leadership Updates

    View All

    HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer

    Brings more than 25 years of experience in building and scaling groundbreaking cardiovascular technologies Will initially focus on launching the Company's FDA-cleared 12-lead ECG system for arrhythmia assessment Will lead the Company's broader commercialization strategy across key growth initiatives, including heart attack detection and the 12-lead ECG extended-wear patch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the appointment of Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026. In this newly created role, Mr. Humbarger will lead commercial strate

    1/22/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    ENvue Medical Appoints Veteran Healthcare-Industry Executive, David Johnson, as Chairman

    ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced the appointment of David Johnson as Chairman of the Board. Mr. Johnson will work alongside CEO, Doron Besser, and the existing leadership team. David Johnson, newly appointed Chairman of ENvue, stated, "We believe ENvue is at the forefront of advanced feeding-tube placement technology, which has been validated in the market and extensively used in the clinic across 38 hospitals in the US. In my opinion, the Company's unique feeding tube placement system that utilizes advanced methods of navigation, integrated sensors and body mapping h

    12/15/25 9:00:00 AM ET
    $ENVB
    $FEED
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors

    HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Dr. Sharon Mates to the board of directors (BOD) of the Company, effective November 2, 2025. "We are delighted to welcome Dr. Sharon Mates to Benitec's Board of Directors," said Jerel Banks, M.D., Ph.D., Chairman and Chief Executive Officer of Benitec Biopharma. "Dr. Mates brings exceptional leadership experience in building successful biotechnology c

    11/3/25 7:00:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $APGN
    $BEAT
    $BFRG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

    SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

    12/6/24 1:47:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Benitec Biopharma Inc.

    SC 13D/A - Benitec Biopharma Inc. (0001808898) (Subject)

    11/18/24 4:36:00 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Annexon Inc.

    SC 13G/A - Annexon, Inc. (0001528115) (Subject)

    11/14/24 7:21:59 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $APGN
    $BEAT
    $BFRG
    Financials

    Live finance-specific insights

    View All

    Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026

    Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) ("Cardio Diagnostics" or the "Company"), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Wednesday, February 18, 2026, at 3 p.m. Central Time. The call will provide an overview of the Company's precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives. Web

    2/17/26 8:35:00 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    BiomX Announces $3.0 Million Private Placement

    NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity ("Private Placement") financing for expected gross proceeds of approximately $3.0 million, before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. About the Private PlacementIn the Private Placement, the Company agreed to issue and sell shares of its Se

    12/29/25 8:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Predictive Oncology Reports Third Quarter 2025 Financial Results and Provides Update on Digital Asset Strategy

    PITTSBURGH, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), an AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on ATH, the native utility token of the Aethir network, today reported financial and operating results for the quarter ended September 30, 2025, and provided a corporate update. Q3 2025 and Recent Highlights: Announced the initiation of a digital asset treasury strategy focused on ATH, the native utility token of the Aethir ecosystem, supported by two private placements pursuant to which the Company received aggregate cash gross proceeds of approximately $50.8 million and in-kind contributions of lo

    11/14/25 5:12:46 PM ET
    $POAI
    Industrial Specialties
    Health Care